from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2w3FJmH on April 28, 2018 at 06:18PM
The Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of several newer options for medication-assisted treatment (MAT) of opioid use disorder.
The scoping document will be open to public comment until 5 p.m. EST May 16.
ICER’s upcoming review is expected to assess the effectiveness and value of a recently-approved monthly buprenorphine injection (Sublocade, Indivior), a buprenorphine implant (Probuphine, Braeburn/Titan), and an investigational buprenorphine extended-release injection (CAM2038, Braeburn) currently under review by the FDA.
These new therapies will be compared to medications commonly used in MAT such as methadone, buprenorphine/naloxone sublingual film (Suboxone, Indivior), and injectable naltrexone (Vivitrol, Alkermes). This list is tentative and subject to change.ICER’s review of options for MAT will be the subject of a November 2018 meeting of the New England Comparative Effectiveness Public Advisory Council, one of ICER’s three independent evidence appraisal committees.
ICER previously reviewed treatment strategies for opioid use disorder in a 2014 report.
To read more about the report, click here.